ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,070.70
      -0.89%
      US Tech 100
      17,112.40
      -1.14%
      Dow Jones
      38,008.68
      -0.98%
      Brent Oil
      86.195
      -1.25%
      Bitcoin
      60,070.87
      -5.89%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. LAVA Therapeutics NV (LVTX)

      7. LAVA Therapeutics NV (LVTX) News

      LVTX

      LAVA Therapeutics NV (LVTX)

      LAVA Therapeutics NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LVTX
      DateTimeSourceHeadlineSymbolCompany
      12:53PMiHub NewswireFeaturedCannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia
      01/25/20248:07AMDow Jones NewsLava Therapeutics Shares Rise as Drug Set for Test With Merck's KeytrudaNASDAQ:LVTXLAVA Therapeutics NV
      11/16/20234:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
      09/06/20237:11AMGlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:LVTXLAVA Therapeutics NV
      08/22/20234:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
      08/22/20237:00AMGlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
      08/15/20236:30AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
      08/14/20237:00AMGlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual ConferenceNASDAQ:LVTXLAVA Therapeutics NV
      06/15/20234:51PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
      06/14/20239:00AMGlobeNewswire Inc.LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayNASDAQ:LVTXLAVA Therapeutics NV
      06/08/20234:06PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
      06/08/20237:00AMGlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
      06/06/20236:02AMEdgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LVTXLAVA Therapeutics NV
      06/05/20236:31PMEdgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LVTXLAVA Therapeutics NV
      06/01/20237:38PMDow Jones NewsStocks to Watch: Lululemon, Lava Therapeutics, Tilly's, OncorusNASDAQ:LVTXLAVA Therapeutics NV
      06/01/20234:20PMGlobeNewswire Inc.LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical DevelopmentNASDAQ:LVTXLAVA Therapeutics NV
      06/01/20238:09AMGlobeNewswire Inc.LAVA Therapeutics to Participate in the Jefferies Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
      05/30/20235:28PMGlobeNewswire Inc.LAVA Announces Annual Meeting of ShareholdersNASDAQ:LVTXLAVA Therapeutics NV
      04/24/20234:07PMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
      04/12/20236:03AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
      04/11/20237:00AMGlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
      03/09/20238:05AMGlobeNewswire Inc.LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of DirectorsNASDAQ:LVTXLAVA Therapeutics NV
      02/16/20237:06AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
      02/16/20237:00AMGlobeNewswire Inc.LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
      02/09/20237:00AMGlobeNewswire Inc.LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceNASDAQ:LVTXLAVA Therapeutics NV
      02/06/20237:07AMEdgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
      02/06/20237:00AMGlobeNewswire Inc.LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical OfficerNASDAQ:LVTXLAVA Therapeutics NV
      01/23/20237:00AMGlobeNewswire Inc.LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
      01/06/20231:07PMGlobeNewswire Inc.LAVA Therapeutics Announces Appointment of New Directors to the BoardNASDAQ:LVTXLAVA Therapeutics NV
      01/03/20237:00AMGlobeNewswire Inc.LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
       Showing the most relevant articles for your search:NASDAQ:LVTX